Medivir’s CEO to BioStock: “The IND approval is a very important milestone”

Medivir has secured FDA approval to proceed with a phase IIb trial evaluating fostrox in combination with Lenvima for second-line treatment of advanced liver cancer. The trial will evaluate the combination’s effect compared to Lenvima alone, building on encouraging phase Ib/IIa results, aiming to bevome the first, approved treatment option in second-line liver cancer. We reached out to CEO Jens Lindberg for a comment.

Read the full interview with Jens Lindberg at biostock.se:

https://www.biostock.se/en/2024/12/medivirs-ceo-the-ind-approval-is-a-very-important-milestone/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/